Gossamer Bio (GOSS) Q3 2026 earnings review
Gossamer filed for approval, but its cash ends in 2027
Gossamer Bio asked American regulators to approve its only medicine, and now needs money to reach the answer. The San Diego company submitted its application for seralutinib, an inhaled treatment for high blood pressure in the lungs, during September. Chief executive Faheem Hasnain said acceptance of that application this year would unlock about $125 million of committed capital. Almost all of the quarter's $38.4 million of revenue came from closing the Chiesi partnership rather than from new work, and cash stood at $51.2 million.
| Revenue excluding the Chiesi termination release | $1.4 million $13.3 million a year ago |
|---|---|
| Net loss | $48.1 million $48.2 million a year ago |
| Cash, equivalents and marketable securities | $51.2 million $57.0 million at the end of June |
| Funding outlook | Unchanged enough to operate into the first quarter of 2027 |
⚖️ Verdict: 🔴 Bearish
The case got worse, because everything Gossamer needs now sits on the far side of one regulatory decision. Its convertible notes all moved into current liabilities, since the filing expects the secured notes to come due in March, and the second closing of committed capital ends if acceptance does not arrive by December. The good news: the application went in during the month management had named, and trial spending halved, so the group consumes much less cash each quarter.
The question now is whether regulators take the seralutinib file before the year ends. If they do, the committed money arrives and Gossamer can pay for a launch and deal with its notes; if they do not, the purchasers walk away and the group must raise capital with an empty quarter ahead of it. The agency's filing decision, expected within about two months, settles it.
🐂 Bull Case
Gossamer Filed Its First Drug Application
Seralutinib is an inhaled medicine for pulmonary arterial hypertension, a disease in which blood pressure inside the lungs rises and the heart weakens. Gossamer has never sold a product, so this application is its first attempt to turn years of laboratory work into revenue from patients.
"Submitting our first NDA marks an important milestone for Gossamer in our continued efforts to bring seralutinib to patients living with PAH," said chairman and chief executive Faheem Hasnain. The San Diego group sent that application, a new drug application in the regulator's language, to the Food and Drug Administration in September, the month it had named three months earlier.
Money follows the paperwork. Acceptance of the filing this year would "unlock up to approximately $125 million in additional committed capital", Hasnain said, because investors in the August financing agreed to pay that sum only on that event. Regulators have not taken the file yet, and the agency "will determine whether to accept the NDA for filing following its initial review".
What to watch: whether the acceptance letter arrives before the end of December. If it does, the committed capital lands and a review begins that could reach an approval decision in the third quarter of 2027.
Trial Costs Fell by More Than Half
Almost all of Gossamer's spending went into PROSERA, the final-stage study of seralutinib that reported in February. With patients off the study and a job-cutting programme completed in September, research and development spending dropped to $18.8 million from $45.5 million a year earlier.
- Seralutinib programme: $18.2 million of the $18.8 million research total
- Total operating costs: $31.2 million, half the year-earlier level
- Job cuts: 73 people, about 46% of staff, announced in March and finished in September
- Share-based pay: $3.8 million, against $2.7 million a year earlier
The saving is real, yet it buys only months, because the group still spends far more than it collects. Gossamer also expects to "incur research and development expenses for the foreseeable future as we continue the development of seralutinib", and preparing a launch costs money long before any pharmacy dispenses a dose.
What to watch: research spending in the fourth quarter, the first full period after the job cuts ended. A figure near this quarter's level would show that the lower cost base holds rather than reflecting a pause in trial invoicing.
Gossamer Took Back Worldwide Rights
Chiesi, an Italian drugmaker, held the licences to sell seralutinib around the world and shared half of any American profit. In July the two sides unwound that deal: Gossamer "reacquired worldwide development and commercial rights to seralutinib" and collected $5 million, with "no upfront cash payment by Gossamer".
What the Italian partner keeps is lighter than what it gave up. It is now entitled to "a capped royalty and certain regulatory and commercial milestone payments": 10% of worldwide sales until those royalties reach $750 million, plus as much as $100 million of milestone payments. The old agreement handed it half of American profits.
What to watch: a new partner for markets outside the United States. Gossamer cannot pay for a global launch on its own, so a licence covering Europe or Japan would be the cheapest way to fund one.
🐻 Bear Case
All of the Notes Are Now Due Within Months
Gossamer owes $84.1 million of convertible notes: a stub of 5% notes maturing in June 2027, and $65.2 million of 7.5% secured notes nominally due in 2030. Those secured notes carry a springing maturity, a clause that pulls their due date forward to 2 March 2027.
The clause bites if more than $4 million of the old notes survives to that date, and the filing states that "the springing maturity is expected to be triggered". Both instruments therefore sit among current liabilities, and working capital turned to minus $39.5 million from plus $104.2 million in December.
Hasnain speaks of "preparing for a potential commercial launch of seralutinib in 2027", while the balance sheet places the whole debt load in the first quarter of that same year. Holders may convert the secured notes into shares rather than ask for cash, although no term obliges them to.
What to watch: a repurchase or exchange of the old notes before 2 March. Retiring about $14.9 million of them, by our math, would leave less than the $4 million trigger and send the secured notes back to their 2030 maturity.
Cash Lasts Into Early 2027 Without New Money
Cash, equivalents and marketable securities came to $51.2 million on 30 September, against $57.0 million three months earlier. That mild decline flatters the picture, because the August placement added about $22.8 million after fees; strip it out and the quarter drained roughly $29 million, by our math.
Two warnings sit in the filing. It repeats "substantial doubt about the Company’s ability to continue as a going concern", and management believes it has "sufficient working capital on hand to fund operations into the first quarter of 2027". A loan term also obliges the borrower to "maintain a minimum amount of liquidity of $40 million" every month.
Acceptance of the application brings a bill as well as money, because Gossamer owes Pulmokine, which licensed seralutinib to it, $5.0 million on that event. The licence also carries further development, commercial and sales milestones that fall due later.
What to watch: the second closing of the August financing, which pays only if regulators accept the application during 2026. Without that payment, early 2027 brings a near-empty account and a debt maturity in the same weeks.
The Chiesi Revenue Has Stopped for Good
Revenue reached $38.4 million, close to triple the year-earlier figure, and almost none of it reflects work performed this quarter. Ending the Chiesi contract released $37.1 million of deferred payments at once. What remains of the cost-sharing income is $1.4 million, against $13.3 million a year ago.
Nothing replaces that income. Gossamer told investors it will "no longer recognize any additional revenue under the agreement in future periods", and the deferred balance on its balance sheet now reads zero. Chiesi also paid half of global development costs, and that support ends with the contract.
What to watch: a new licence or research funding agreement signed before approval. One would show that another drugmaker will pay for seralutinib's commercial rights, which is also the cheapest way to cover a launch.
Warrants Could Add More Shares Than Exist
Gossamer raised its August money by selling pre-funded warrants, which are rights to buy shares for almost nothing, and promised two further batches: one at the second closing, one if regulators approve seralutinib. Accounting for those promises produced a $96.2 million charge on issuance, because their fair value exceeded what purchasers paid.
That charge, net of later gains, left a $56.5 million remeasurement loss on the warrants, which turned the quarter's operating profit into a net loss of $48.1 million. The loss is an accounting entry. The shares behind it are not: warrants, options and notes could bring 8.4 million shares, against 6.1 million outstanding.
What to watch: the share count after the second closing. Those warrants convert into a number of shares that nobody can fix in advance, so today's holders cannot yet know how much of the drug they will still own.
👓 Other Themes
Regulators Decide Whether to Review the Filing
Regulators set the clock from here. In February the final-stage study improved walking distance by 13.3 metres with a p-value of 0.0320, "missing the prespecified alpha threshold of 0.025". Gossamer reported in June that reviewers treated the size and the significance of that effect as issues for the review rather than grounds to refuse the filing.
One Share for Every Eighty
Gossamer turned every 80 shares into one on 10 September, and Nasdaq confirmed on 25 September that it had "regained compliance with Nasdaq Listing Rule 5450(a)(1)". Owners hold the same fraction of the same business as before. The exercise matters because a delisting would let noteholders demand repayment.
💲 Other KPIs
Overhead barely moved, rising 2.6% from a year ago. Legal fees and share-based pay each added about $0.9 million, while commercial preparation costs fell $1.2 million. A severance charge in the first quarter still makes the nine-month comparison far larger. Gossamer expects this line to climb once regulators accept its filing.
Money owed to trial contractors shrank by nearly two thirds since December, when it stood at $21.7 million. Accrued research costs are invoices for work already done, so the fall confirms that little study activity remains to be billed. The same wind-down drained $13.6 million of cash over nine months.
The charge hardly moved from a year ago, although principal is now far smaller after June's exchange. Contractual interest came to $1.5 million; amortisation of the discount on the secured notes made up most of the rest, and that part consumes no cash. Those secured notes pay 7.5%.
🔮 Guidance
Unchanged. Gossamer again says its money lasts into the first quarter of 2027, the fourth quarter running with that wording. By our math, $51.2 million at this quarter's rate of use covers about 1.8 quarters, so the statement and the arithmetic agree. The account fell 10% during the quarter, against 43% in the spring, because August's placement arrived.
New. Purchasers agreed in August to pay this sum once regulators accept the seralutinib filing, which is about 2.4 times the cash Gossamer holds. The promise is dated: "If the Second Closing does not occur on or before December 31, 2026", it terminates. A further $100 million could follow on approval, if warrant holders pay cash.
Unchanged. The filing repeats that "seralutinib could be eligible for an FDA approval decision in the third quarter of 2027", and that date still depends on acceptance. Every month the agency takes to decide on acceptance shifts the decision later, which matters because the notes come due in the first quarter of that year.
❓ Key Questions
Will regulators accept the filing before January?
The second closing pays only on acceptance during 2026, and the obligation ends on 31 December. Hasnain has not said what Gossamer would do with the funding gap if the letter arrives in January instead.
What is the plan for the old notes?
Leaving more than $4 million of the 5% notes outstanding on 2 March pulls the secured notes forward to that date. Gossamer has not described how it intends to retire, exchange or refinance that stub.
How much will a launch cost?
The filing says administrative spending will rise to support commercial planning, without a figure. Readers need the size of the sales organisation and the marketing budget to judge how much capital a 2027 launch needs.
When does the lung-disease study restart?
Gossamer paused enrolment in SERANATA, its study of seralutinib in pulmonary hypertension with interstitial lung disease, and still calls that indication a focus. It has given neither a restart date nor a cost.
Who sells seralutinib outside America?
Reacquiring worldwide rights returned Europe, Japan and other markets to a company with $51 million of cash. Management has not said whether it is seeking a new licensee for those territories.